10-K: Onconetix Pursues Realbotix Merger Amidst Financial Challenges

Onconetix, a commercial-stage biotech, is moving forward with a reverse merger to acquire Realbotix, aiming to bolster its financial position and product pipeline while grappling with significant losses and internal control weaknesses.

Summary

• Onconetix, Inc. (formerly Blue Water Vaccines Inc. and Blue Water Biotech, Inc.) is a commercial-stage biotechnology company focused on men's health and oncology, primarily through its Proclarix diagnostic test.
• The company acquired Proteomedix on December 15, 2023, which owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union.
• Commercialization of ENTADFI, an FDA-approved pill for BPH, was abandoned due to time, resources, cash runway, and indebtedness, with assets fully impaired by December 31, 2025.
• On February 11, 2026, Onconetix entered into a Share Exchange Agreement to acquire Realbotix Corp. and its subsidiary, Realbotix, LLC, in exchange for newly issued shares of Onconetix Common Stock.
• The percentage of Onconetix's fully diluted shares to be owned by the Seller (Simulacra Corporation) post-closing will range from 75% to 90%, depending on Onconetix's Net Cash at closing (between $12.5 million and $20.0 million).
• The Realbotix transaction is subject to several closing conditions, including Onconetix having at least $12.5 million in Net Cash and securing an equity line of credit for up to $125.0 million.
• Onconetix reported a net loss of $14.0 million for the year ended December 31, 2025, significantly lower than the $58.7 million loss in 2024.
• Revenue decreased by approximately $1.7 million to $0.8 million in 2025 from $2.5 million in 2024, primarily due to a $2.3 million reduction in development services revenue, partially offset by a $0.6 million increase in other license revenue.
• Product sales from Proclarix remained relatively consistent at approximately $0.2 million in both 2025 and 2024.
• The company incurred goodwill impairment losses of $11.5 million in 2025 and $32.3 million in 2024, and intangible asset impairment of $10.3 million in 2024.
• As of December 31, 2025, Onconetix had cash of approximately $5.2 million, a working capital deficit of $3.1 million, and an accumulated deficit of $131.2 million.
• Cash used in operating activities was $9.7 million in 2025. As of March 11, 2026, the cash balance was approximately $3.6 million.
• The company completed Series D and Series E PIPE financings in September and October 2025, respectively, providing net cash proceeds of $9.3 million and $6.25 million.
• Onconetix regained compliance with Nasdaq's minimum bid price and filing rules in July 2025, following a 1-for-85 reverse stock split on June 13, 2025, and timely filings. It is subject to a Mandatory Panel Monitor through July 7, 2026.
• Material weaknesses in internal controls over financial reporting were identified, including inadequate segregation of duties, ineffective risk assessment, and insufficient accounting resources.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly speculative situation. While strategic moves like the Realbotix merger and Proclarix's market traction offer potential, the severe financial distress, ongoing losses, and internal control weaknesses present significant risks to the company's viability.

Positives

• Net loss significantly decreased to $14.0 million in 2025 from $58.7 million in 2024.
• Proclarix, the company's lead diagnostic product, is CE-marked and approved for sale in the European Union, with sales efforts continuing and growing revenues expected in 2026 and beyond.
• Proclarix is included in the clinical practice guidelines of both the European Association of Urology (EAU) and the American Urological Association/Society of Urologic Oncology (AUA/SUO), validating its clinical value.
• A new validation study (PRIME Study) for Proclarix in the U.S. is scheduled to begin in 2026 with LabCorp, potentially expanding market access.
• Secured $9.3 million in net cash from Series D PIPE financing and $6.25 million in net cash from Series E PIPE financing in late 2025, providing near-term operational support.
• Successfully regained compliance with Nasdaq's minimum bid price and filing requirements in July 2025, maintaining its listing.
• Entered into a licensing agreement with Immunovia AB in September 2025, generating $0.6 million in license revenue in 2025 and potential future royalties.
• The company's quality management system is ISO 13485:2016 certified, and Proclarix is IVDR compliant, demonstrating adherence to high quality standards for diagnostic tests.

Negatives

• Incurred substantial net losses since inception, with an accumulated deficit of $131.2 million as of December 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern for one year from the date of issuance of the financial statements.
• Cash balance was approximately $5.2 million as of December 31, 2025, and further decreased to $3.6 million as of March 11, 2026, which is insufficient to fund operations for one year.
• Experienced a significant decrease in total revenue in 2025, primarily due to the completion of a non-recurring development services contract.
• Abandoned commercialization of ENTADFI, an FDA-approved product, and fully impaired its assets by December 31, 2025, indicating a failed product strategy.
• Recorded significant goodwill impairment losses of $11.5 million in 2025 and $32.3 million in 2024, reflecting a reduction in the fair value of acquired businesses.
• Identified material weaknesses in internal controls over financial reporting, including inadequate segregation of duties, ineffective risk assessment, and insufficient accounting resources.
• Relies heavily on third-party manufacturers, with main suppliers being single-source, posing supply chain risks.
• The Realbotix transaction, if completed, will result in significant dilution for existing shareholders, with the Seller potentially owning 75-90% of the fully diluted shares.
• The company has a significant customer concentration, with Immunovia accounting for 100% of development service revenue and other revenue, and 92% of product sales revenue in 2025.

Risks

• Failure to complete the Realbotix Transaction or completion on different, less favorable terms.
• If completed, the Realbotix Transaction may not achieve its intended results and could lead to unanticipated liabilities.
• Stockholders may experience significant ownership dilution from the Realbotix Transaction without commensurate benefit.
• Difficulty in successfully integrating Onconetix and Realbotix businesses, potentially causing management and business disruptions.
• Incurrence of significant transaction costs related to the Realbotix Transaction, many of which are non-recoverable if the transaction fails.
• Substantial doubt about the ability to continue as a going concern due to recurring net losses and insufficient capital.
• Inability to raise additional capital when needed, forcing delays, reductions, or termination of commercialization efforts or operations.
• Significant current liabilities that could lead to bankruptcy if creditors demand immediate payment and the company cannot comply.
• Lengthy, time-consuming, and unpredictable marketing approval processes in the United States for Proclarix, especially with the FDA phasing out enforcement discretion for LDTs.
• Complete dependence on the success of Proclarix; failure to commercialize or significant delays would harm the business.
• Inability to gain and retain market acceptance for Proclarix among physicians, patients, and payors.
• Intense competition in the molecular diagnostics field from larger, well-established companies with greater resources.
• Reliance on third-party manufacturers and logistics companies for Proclarix, including single-source suppliers, posing risks of disruptions or increased costs.
• Difficulty and costliness in protecting proprietary intellectual property rights, with potential for third-party infringement or challenges to patent validity.
• Reliance on licensed intellectual property; loss of rights could prevent continued development or commercialization.
• High volatility in the market price of common stock, potentially leading to loss of investment.
• Risk of delisting from Nasdaq if continued listing requirements are not met, despite current compliance.
• Exposure to product liability lawsuits, which could result in substantial liabilities and limit commercialization.
• Security threats to information technology infrastructure and physical buildings, potentially leading to liability and reputational damage.
• Difficulties in managing future organizational growth, including attracting and retaining qualified personnel.
• Potential misconduct and errors by employees or third-party service providers, leading to adverse effects on business and reputation.
• Adverse effects from macroeconomic pressures, natural disasters, pandemics, and man-made problems.
• Changes in healthcare regulations and reform initiatives, potentially impacting pricing, reimbursement, and business operations.
• Risk of short squeeze due to sudden increase in demand for common stock exceeding supply, leading to price volatility.
• The issuance or conversion of securities, including preferred stock and warrants, would result in significant dilution for existing shareholders.

Future Outlook

Onconetix anticipates growing revenues from Proclarix sales in 2026 and beyond, which are expected to offset some commercial scale-up and development expenses. The company expects overall expenses to increase due to commercialization efforts, additional hiring, public company operations, and intellectual property protection. Significant additional capital will be required to fund continued operations, including the commercialization of Proclarix and future product candidates. The pending Realbotix transaction is expected to provide strategic and financial benefits, but its completion and successful integration are critical. Management plans to pursue further equity or debt financing to support operations and strategic initiatives.

Management Comments

• Management believes that current cash balance is not sufficient to fund operations for one year from the date of issuance of the consolidated financial statements for the year ended December 31, 2025.
• Management plans for funding operations include generating product revenue from sales of Proclarix and pursuing additional equity or debt financing.
• Karina M. Fedasz, Interim CEO and CFO, has over two decades of experience helping companies raise capital, model and forecast business, manage cash flow, and conduct mergers and acquisitions, bringing a dynamic, data-driven, high-growth mindset.
• The Board of Directors, including Andrew Oakley (Non-Executive Chairman), Sarah Romano, Dr. Thomas Meier, and Timothy Ramdeen, possess extensive expertise in life sciences, business, finance, public company reporting, and capital markets.

Industry Context

StockSavvy.ai notes that Onconetix operates in the intensely competitive molecular diagnostics field, characterized by rapid technological changes and evolving standards. The prostate cancer diagnostics market is large, with many established competitors like OPKO Health (4Kscore) and Beckman Coulter (phi score). Onconetix's Proclarix aims to address the unmet need for improved patient stratification in the diagnostic grey zone, where overdiagnosis and overtreatment are prevalent. The company's IVDR compliance and ISO 13485:2016 certification for Proclarix position it favorably against competitors who may face delays in meeting new EU regulations. The shift from vaccine development to men's health and oncology aligns with a growing demand for specialized diagnostic tools in regions with robust healthcare infrastructure.

Comparison to Industry Standards

• Proclarix offers comparable or superior clinical performance compared to existing tests like %fPSA, 4Kscore (OPKO Health, Inc.), and phi score (Beckman Coulter, Inc.).
• Unlike urine-based tests such as SelectMDx (MdxHealth SA) which require prostate massage, Proclarix is blood-based, making it minimally invasive and highly reproducible, fitting into current lab workflows.
• Proclarix's use of immunoassay-based technology allows for easy automation on existing laboratory instrumentation, a competitive advantage over tests like PCA3 (Gen-Probe Inc.) or ExoDx IntelliScore (Exosome Diagnostics, Inc.) which may require specialized equipment or cold storage.
• The objective result generation and genetics-guided discovery of cancer-related biomarkers in Proclarix provide a clear diagnostic support, addressing the confusion often associated with traditional PSA test results.
• Proclarix is complementary to MRI assessment, offering a valuable tool for identifying men at risk of clinically significant prostate cancer before or after MRI, especially in cases of indeterminate MRI results, outperforming PSA density in specificity (25% vs 13%, p=0.004 at 100% sensitivity in one evaluation).

Management Changes

Corporate Governance

Legal Proceedings

• Currently not a party to any material legal proceedings.
• The merger agreement with Ocuvex Therapeutics, Inc. was terminated effective September 24, 2025, with Onconetix paying a termination fee of $302,343.55.

Related Party Transactions

• On January 23, 2024, Onconetix issued a $5.0 million non-convertible debenture to Altos Ventures (PMX Investor), a 5% stockholder, which was settled through the issuance of shares on September 24, 2024.
• Dr. Thomas Meier, a director, provides consulting services to Proteomedix through an affiliated firm. Onconetix recorded approximately $33,000 in related expenses in 2025, with $16,500 included in accounts payable as of December 31, 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution from current and future capital raises (Series D, E, ELOC, Realbotix transaction) and potential loss of investment due to going concern doubts and volatile stock price. The reverse stock splits also impact share count and price.
• **Employees**: Experienced headcount reductions related to the abandonment of the ENTADFI program. Future growth plans include hiring additional personnel, but the company's financial instability could affect retention and recruitment.
• **Customers (Laboratories, Hospitals)**: Proclarix offers a valuable diagnostic tool for prostate cancer, potentially improving patient care and reducing unnecessary biopsies. However, reliance on third-party manufacturers and the company's financial health could impact product availability and support.
• **Suppliers/Creditors**: The company's significant current liabilities and going concern doubt pose risks to timely payments. The Veru Settlement Agreement resolved a major debt, but overall financial health remains a concern.
• **Regulatory Bodies**: Onconetix is subject to ongoing Nasdaq monitoring and must address internal control weaknesses, indicating increased scrutiny and compliance efforts.

Next Steps

• Commercialize Proclarix in Europe and the United States (via LabCorp).
• Conduct a new validation study (PRIME Study) for Proclarix with LabCorp starting in 2026.
• Complete the Realbotix Share Exchange Agreement, subject to closing conditions including minimum net cash and securing a $125.0 million equity line of credit.
• Hire additional personnel to support commercialization and growth.
• Obtain, maintain, expand, and protect the intellectual property portfolio.
• Pursue additional equity or debt financing to fund continued operations and strategic initiatives.
• Remediate identified material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

Onconetix faces severe financial distress, evidenced by substantial accumulated losses ($131.2 million), a working capital deficit ($3.1 million), and a critically low cash balance ($3.6 million as of March 11, 2026), leading to substantial doubt about its ability to continue as a going concern. While recent capital raises provide temporary relief, the company's inability to generate sufficient revenue, coupled with significant goodwill impairments and identified material weaknesses in internal controls, paints a bleak operational picture. The proposed Realbotix merger, while a strategic pivot, introduces further uncertainty and significant dilution for existing shareholders, with its success contingent on substantial future capital and successful integration. Given the high speculative nature, persistent financial instability, and operational challenges, a seasoned investor would likely recommend a strong sell to mitigate further risk.

Keywords

Prostate Cancer Diagnostics, Biotechnology, SEC Filing, 10-K, Reverse Merger, Realbotix, Proclarix, Going Concern, Capital Raise, Nasdaq Compliance, Intellectual Property, Financial Performance, Corporate Governance, Risk Factors, Men's Health, Oncology